Drugs · Brain health technique
Lipid-Lowering Drugs
Evidence grade: Context Dependent
Therapies that reduce LDL cholesterol and vascular inflammation, including statins (atorvastatin, rosuvastatin, simvastatin), PCSK9 inhibitors (alirocumab, evolocumab), and ezetimibe (Zetia®). Used to prevent atherosclerosis and support cerebral blood flow.
- Practice
- Drugs
- Principle
- Treatment
- Tactic
- Metabolic & Vascular Optimization Drugs
- Health domains
- vascular
- Evidence grade
- Context Dependent
- Strength of evidence
- Medium
- Cost
- High
- Effort
- Low
- Time commitment
- Low
How to practice Lipid-Lowering Drugs
Lipid screening should begin as early as possible. Measure ApoB and lp(a) at minimum, and targets should be based on overall risk and presence of existing disease. If levels are far from target and nutritional strategies have not meaningfully helped, consider treatment. Optimal lipid lowering strategy depends on your blood biomarkers, insurance coverage, budget, and risk tolerance.
The evidence behind Lipid-Lowering Drugs
High LDL and vascular inflammation accelerate atherosclerosis, small-vessel disease, and dementia risk. RCTs show that statins and PCSK9 inhibitors lower cardiovascular events; observational data suggest reduced dementia risk, especially with long-term use. Mechanism: improved endothelial function, nitric oxide signaling, and plaque stabilization maintain brain perfusion. Evidence strong for vascular protection, moderate for direct neuroprotection.
More Drugs techniques
Take control of your brain health
BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.